SYNERGISTIC EFFECT OF ROSUVASTATIN WITH OXYCODONE HYDROCHLORIDE SUSTAINED-RELEASE TABLETS IN THE TREATMENT OF CANCER PAIN IN PATIENTS WITH SEVERE BREAST CANCER AND ITS EFFECT ON INFLAMMATORY FACTORS

Yanli Gao¹, Baoqi Zhang², Xuetang Li¹, Daoyan Wang¹, Yuling Sui¹, Guangcai Li¹, Zongqin Yao³, Feng Wang^{4, *}

¹Department of Pharmacy, Linyi Central Hospital, Linyi, PR China - ²Department of Surgery, Linyi Central Hospital, Linyi, PR China - 

³Department of Cardiology, Linyi central hospital, Linyi, PR China - ⁴Department of Breast Surgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, PR China

Objective: The objective of this study was to investigate the synergistic effect of rosuvastatin with oxycodone hydrochloride sustained-release tablets in the treatment of cancer pain in patients with severe breast cancer and its effect on inflammatory factors. 

Methods: A total of 90 patients admitted to our department of oncology with severe breast cancer from June 2018 to July 2019 were randomly divided into a control group (n=45) and an experimental group (n=45). The patients in the control group were treated with oxycodone hydrochloride sustained-release tablets on the basis of conventional chemotherapy. The patients in the experimental group were treated with rosuvastatin on the basis of the control group. The levels of inflammatory factors (tumour necrosis factor (TNF)-α, interleukin-6 (IL-6)) were detected by enzyme-linked immunosorbent assay. The control group and experimental group were compared in terms of clinical efficacy, adverse reactions, digital grading scores, number of outbreaks of pain, and the effects of the inflammatory factors. 

Results: After treatment, the total effective rate of the control group was 75.56%, and that of the observation group was 93.33%. The total effective rate of the observation group was significantly higher than that of the control group (P<0.05). The number of outbreaks of pain, the numerical grading method scores, and the effective dose of oxycodone hydrochloride sustained-release tablets for patients in the experimental group were significantly lower than those for patients in the control group, and the difference was statistically significant (P<0.01). The levels of TNF-α and IL-6 in patients in both the experimental group and the control group were significantly lower after treatment than they were before treatment, and the levels of TNF-α and IL-6 in patients in the experimental group were lower than those in patients in the control group (P<0.05). After treatment, the incidence of adverse reactions was 24.44% in the observation group and 26.67% in the control group. There was no significant difference between the two groups in terms of the incidence of adverse reactions (P>0.05). 

Conclusions: Rosuvastatin could potentially relieve cancer pain in patients with severe breast cancer treated with oxycodone hydrochloride sustained-release tablets. Rosuvastatin has a synergistic effect that can effectively reduce inflammatory factors and improve treatment efficacy and is therefore worthy of application and promotion.